Voyageur Pharmaceuticals Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VYYRF research report →
Price Chart
About the company
Voyageur Pharmaceuticals Ltd. is dedicated to extracting active pharmaceutical ingredients (APIs) from various mineral resources. The firm's strategic objectives include manufacturing radiocontrast compounds derived from barium and iodine, in addition to developing pharmaceuticals that incorporate bromine.
- CEO
- Brent Willis
- IPO
- 2017
- Employees
- 6
- HQ
- Calgary, AB, CA
Get TickerSpark's AI analysis on VYYRF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $16.15M
- P/E
- -5.76
- PEG
- 0.13
- P/S
- 474.91
- P/B
- 54.82
- EV/EBITDA
- -5.80
- Div Yield
- 0.00%
- Gross Margin
- -4603.48%
- Op Margin
- -8038.56%
- Net Margin
- -8033.93%
- ROE
- -403.29%
- ROIC
- -847.23%
Latest fiscal year · YoY change
- Revenue
- $11.67K+0.0%
- Gross Profit
- $-1,221,597+0.0%
- Op Income
- $-3,528,461
- Net Income
- $-3,528,461-206605.4%
- EPS
- $-0.02-71.0%
- OCF Growth
- -855.9%
- FCF Growth
- -855.9%
- 52W High
- $1.03
- 52W Low
- $0.00
- 50D MA
- $0.16
- 200D MA
- $0.11
- Beta
- 0.29
- RSI (14)
- 47
- Avg Volume
- 29.40K
No earnings-call transcripts are available for VYYRF yet.
- Free Float
- 90.5%
- Shares Outstanding
- 179.48M
- Float Shares
- 162.38M
Our VYYRF coverage
Recent articles, reports, and earnings notes.
No research on VYYRF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VYYRF report →Voyageur Pharmaceuticals Announces Completion of Shares for Debt Settlement
newsfilecorp.com · Oct 2
Voyageur Pharmaceuticals Announces Proposed Issuance of Shares for Debt
newsfilecorp.com · Sep 24
Voyageur Pharmaceuticals Achieves First Milestone on Feasibility Study for Iodine Production; Secures USD $1 Million Payment
thenewswire.com · Sep 9
Voyageur Pharmaceuticals Advances Mueller Iodine Extraction Process with 99.8% Purity Results and Planned Field Pilot Testing
thenewswire.com · Aug 10
Voyageur Pharmaceuticals Announces the Engagement of Red Cloud Securities as Market Maker
newsfilecorp.com · Jul 17
Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility
thenewswire.com · Jun 23
Voyageur Pharmaceuticals Evaluating Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility, a Multi-Phase Investment Expected to Generate Significant Economic Impact and High-Skilled Jobs; Competitive Site Selection Process Underway
thenewswire.com · Jun 18
Voyageur Pharmaceuticals Ltd. Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support at Frances Creek Barite Project
thenewswire.com · Jun 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.